Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Charlie Evans, 13, who suffers from severe food allergies and eosinophilic esophagitis (EoE), takes part in an NIH-funded study at Cincinnati Children's hospital. The NIH dismissed the hospital's ...

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook.

This is an active lawsuit, and none of the allegations against the defendant(s) have been proven. The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...

From relentless itching and painful flare-ups to sleepless nights and emotional exhaustion, eczema can take a serious toll on both physical and mental well-being. 1,2 For millions of people, it means ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...